Denosumab increases bone density, cuts fracture risk in prostate cancer survivors

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, will appear in the 20 August New England Journal of Medicine and is receiving early online release...

Read the whole article on

More from